Scarica l'app Stockscreener
35.75
2.14%
0.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRNX Giù?
Forum
Previsione
Precedente Chiudi:
$35.00
Aprire:
$35
Volume 24 ore:
743.64K
Relative Volume:
0.63
Capitalizzazione di mercato:
$3.77B
Reddito:
$18.07M
Utile/perdita netta:
$-496.39M
Rapporto P/E:
-6.9643
EPS:
-5.1333
Flusso di cassa netto:
$-419.52M
1 W Prestazione:
+4.17%
1M Prestazione:
-2.77%
6M Prestazione:
-25.04%
1 anno Prestazione:
+15.88%
Intervallo 1D:
$34.79
$36.40
Intervallo di 1 settimana:
$32.70
$36.40
Portata 52W:
$25.83
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Nome
Crinetics Pharmaceuticals Inc
Settore
Industria
Telefono
858-450-6464
Indirizzo
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
35.75 | 3.70B | 18.07M | -496.39M | -419.52M | -5.1333 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-12 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-10 | Iniziato | Goldman | Neutral |
| 2025-03-25 | Iniziato | Stifel | Buy |
| 2025-02-11 | Iniziato | TD Cowen | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Peer Perform |
| 2025-01-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-01-16 | Iniziato | Morgan Stanley | Overweight |
| 2023-12-21 | Iniziato | Jefferies | Hold |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Iniziato | Oppenheimer | Outperform |
| 2023-04-24 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Robert W. Baird | Outperform |
| 2021-11-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-11-23 | Iniziato | Evercore ISI | Outperform |
| 2021-06-18 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Iniziato | ROTH Capital | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-13 | Iniziato | JP Morgan | Neutral |
| 2018-08-13 | Iniziato | Leerink Partners | Outperform |
| 2018-08-13 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie
Citizens reiterates Crinetics stock rating on strong launch data By Investing.com - Investing.com Canada
CRNX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $81 - GuruFocus
H.C. Wainwright reiterates Crinetics stock rating on durability data By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Crinetics (CRNX) Reveals Promising Long-Term Results for Palsoni - GuruFocus
In CAH trial, daily pill cut steroid doses as hormone levels fell - Stock Titan
Crinetics shows Phase 2 success for atumelnant in reducing hormones and glucocorticoid use in CAH patients - Pluang
Crinetics (CRNX) Shares New Phase 2 Study Results on Atumelnant - GuruFocus
Crinetics presents phase 2 data for CAH treatment atumelnant By Investing.com - Investing.com South Africa
Crinetics Presents Full Results From Phase 2 Trial of - GlobeNewswire
Crinetics Pharmaceuticals Presents Long-Term Efficacy and Safety Data for PALSONIFY at ENDO 2026 - Quiver Quantitative
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control - GlobeNewswire Inc.
Sector Gamma AS Makes New $5.35 Million Investment in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Crinetics Pharmaceuticals, Inc. (CRNX) reports Q1 loss, beats revenue estimates - MSN
Positive Outlook for Crinetics (CRNX) After Camurus' Regulatory Setback - GuruFocus
Analysts estimate Crinetics Pharmaceuticals, Inc. (CRNX) to report a decline in earnings: What to look out for - MSN
CRNX Reiterated by Citizens -- Price Target Maintained at $95 - GuruFocus
Citizens reiterates Crinetics stock rating on Palsonify launch strength - Investing.com UK
Crinetics Pharmaceuticals' (CRNX) Market Outperform Rating Reaffirmed at Citizens Jmp - MarketBeat
Citizens reiterates Crinetics stock rating on Palsonify launch strength By Investing.com - Investing.com South Africa
Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why - Insider Monkey
Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by GW&K Investment Management LLC - MarketBeat
Crinetics' Everyday Advocacy initiative to support Cushing's care - Cushing's Disease News
WINTON GROUP Ltd Sells 39,816 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Understanding the Setup: (CRNX) and Scalable Risk - Stock Traders Daily
Geode Capital Management LLC Trims Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
A Look At Crinetics Pharmaceuticals (CRNX) Valuation As New Endocrine Data Heads To ENDO 2026 - Yahoo Finance
Acromegaly Market Shows Strong Future Potential with Increasing Industry Investments by 2036 – DelveInsight | Crinetics, Camurus, Chiesi, Debiopharm International SA, AstraZeneca, Marea Therapeutics - Barchart.com
Crinetics Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations - marketscreener.com
Crinetics launches patient education program for endocrine diseases - Investing.com UK
Crinetics launches patient education program for endocrine diseases By Investing.com - Investing.com Australia
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities - The Manila Times
New Everyday Advocacy tools help endocrine patients navigate care - Stock Titan
Crinetics (NASDAQ: CRNX) CEO reports 1.94M share gifts and trust transfers - Stock Titan
Crinetics Pharmaceuticals Highlights Positive Clinical Data for PALSONIFY™ and Atumelnant at ENDO 2026 Conference - Quiver Quantitative
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations - The Manila Times
What Do Analysts Say About Crinetics Pharmaceuticals (CRNX)? - Insider Monkey
5 Under-the-Radar Stocks with Massive Upside for 2026 - Insider Monkey
The Technical Signals Behind (CRNX) That Institutions Follow - Stock Traders Daily
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 - The Manila Times
Crinetics management to meet investors at Jefferies healthcare event - Stock Titan
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? - AOL.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN
Precision Trading with Crinetics Pharmaceuticals Inc. (CRNX) Risk Zones - Stock Traders Daily
Crinetics Pharmaceuticals Inc Azioni (CRNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):